share_log

和鉑醫藥-B：內幕消息 - 與阿斯利康訂立新型腫瘤靶向療法之許可及選擇權協議

HBM HOLDINGS-B: INSIDE INFORMATION - ENTERING INTO LICENSE AND OPTION AGREEMENT WITH ASTRAZENECA FOR NOVEL TUMOR TARGETED THERAPIES

Hong Kong Stock Exchange ·  May 23 06:18
Summary by Futu AI
和鉑醫藥-B（02142.HK）近日宣布其全資子公司諾納生物與全球生物製藥公司阿斯利康簽訂了一項許可及選擇權協議。該協議涉及一種臨床前階段的單克隆抗體，用於開發新型腫瘤靶向療法。根據協議，諾納生物將在交易完成時獲得1900萬美元的預付款，並有機會在達成特定開發、監管和商業里程碑時，獲得最高575百萬美元的里程碑付款，以及基於淨銷售額的分級特許權使用費。此外，若阿斯利康行使選擇權，諾納生物將獲得額外付款。該協議是和鉑醫藥Harbour Mice®技術平台的一個重要里程碑，展示了公司技術的潛力和創新能力。董事會認為，此協議符合公司及其股東的整體最佳利益。公告中亦提及，前瞻性陳述存在風險和不確定性，實際結果可能與預期存在差異。公告由公司主席及執行董事王勁松博士於2024年5月23日發出。
和鉑醫藥-B（02142.HK）近日宣布其全資子公司諾納生物與全球生物製藥公司阿斯利康簽訂了一項許可及選擇權協議。該協議涉及一種臨床前階段的單克隆抗體，用於開發新型腫瘤靶向療法。根據協議，諾納生物將在交易完成時獲得1900萬美元的預付款，並有機會在達成特定開發、監管和商業里程碑時，獲得最高575百萬美元的里程碑付款，以及基於淨銷售額的分級特許權使用費。此外，若阿斯利康行使選擇權，諾納生物將獲得額外付款。該協議是和鉑醫藥Harbour Mice®技術平台的一個重要里程碑，展示了公司技術的潛力和創新能力。董事會認為，此協議符合公司及其股東的整體最佳利益。公告中亦提及，前瞻性陳述存在風險和不確定性，實際結果可能與預期存在差異。公告由公司主席及執行董事王勁松博士於2024年5月23日發出。
And Platinum Pharmaceutical-B (02142.HK) recently announced that its wholly-owned subsidiary Nona Bio has signed a licensing and options agreement with global biopharmaceutical company Aslikon. The protocol involves a preclinical monoclonal antibody for the development of novel tumor-targeted therapies. Under the agreement, Nona Bio will receive an upfront payment of $1900 million upon completion of the transaction and have the opportunity to receive a milestone payment of up to $575 million when certain development, regulatory and commercial milestones are met, as well as a rating franchise fee based on net sales. In addition, if Aslicon exercises its option, the Nona creature will receive an additional payment. The agreement is a significant milestone with Platinum Pharmaceuticals Harbour Mice® technology platform, demonstrating...Show More
And Platinum Pharmaceutical-B (02142.HK) recently announced that its wholly-owned subsidiary Nona Bio has signed a licensing and options agreement with global biopharmaceutical company Aslikon. The protocol involves a preclinical monoclonal antibody for the development of novel tumor-targeted therapies. Under the agreement, Nona Bio will receive an upfront payment of $1900 million upon completion of the transaction and have the opportunity to receive a milestone payment of up to $575 million when certain development, regulatory and commercial milestones are met, as well as a rating franchise fee based on net sales. In addition, if Aslicon exercises its option, the Nona creature will receive an additional payment. The agreement is a significant milestone with Platinum Pharmaceuticals Harbour Mice® technology platform, demonstrating the potential and innovative capabilities of the company's technology. The Board considers that this agreement is in the overall best interests of the Company and its shareholders. It is also noted in the announcement that there are risks and uncertainties in the forward-looking statements and that actual results may differ from expectations. The announcement was made by Dr. Wang Jin-song, Chairman and Executive Director, on 23 May 2024.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.